Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery

This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentVariational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel payloads for antibody drug conjugatesSign In or Create an AccountEmail AddressContinueor View more offersArticle contentVANCOUVER, British Columbia — Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significant improvements in algorithmic performance and target coverage through platform architecture design, as well as extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates (ADCs) and related modalities.Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle content“Enki 4 is a massive step forward for our platform,” Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentsaid Ali Saberali, Co-Founder & Head of Platform at Variational AI.Article content“We’ve re-architected Enki and improved the underlying algorithms to expand target and modality coverage, while operating faster to deliver even better performance for our partners.”Article contentEnki 4 now supports the rapid generation of novel, potent, selective, and synthesizable lead-like structures pre-trained on 760 drug targets, a 28% increase over the previous Enki version’s 592 targets, with more to be released soon. The update delivers enhanced performance across more than 12 target classes, including: GPCRs, kinases, ion channels, proteases, oxidoreductases, hydrolases, and others.Article content“This Enki release continues our process of continuous model innovation” Article contentadded Handol Kim, Co-Founder & CEO.Article content “Enki 4 enables our biotech partners to start with novel leads they would not have discovered using traditional methods. Our goal is to eliminate hit ID and hit-to-lead, generating molecules ready to go directly into lead optimization.”Article contentFor more information about Enki 4 and to access the full list of 760 targets, visit variational.ai/enki or contact bd@variational.ai.Article contentAbout Variational AIArticle contentVariational AI is a generative AI drug discovery company based in Vancouver, Canada. Founded by machine learning researchers from MIT, Caltech, Google Research, Microsoft Research, and D-Wave Quantum, its proprietary Enki™ platform uses state-of-the-art generative AI models to design novel, optimized small molecules with improved probability of success for biopharmaceutical partners. variational.aiArticle contentArticle contentArticle contentView source version on businesswire.com: Article content https://www.businesswire.com/news/home/20260407073931/en/Article contentArticle contentContactsArticle contentMedia Contact Article contentArticle contentValentin Beuchillot, Senior Manager BD & Marketing —Article contentvalentin@variational.aiArticle content— +1 236-818-8624Article contentTrending William Watson: Open the highway, you crazy New Brunswickers! FP Comment The accountant shortage is starting to add up despite an easier tax filing season Personal Finance Posthaste: One year in, no sign that Trump is winning the tariff war News Opinion: The world has an energy problem and Canada is the solution Energy Toronto home sales rise as buyers benefit from ‘substantial negotiating power’ Real Estate Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. William Watson: Open the highway, you crazy New Brunswickers! FP Comment The accountant shortage is starting to add up despite an easier tax filing season Personal Finance Posthaste: One year in, no sign that Trump is winning the tariff war News Opinion: The world has an energy problem and Canada is the solution Energy Toronto home sales rise as buyers benefit from ‘substantial negotiating power’ Real Estate